Curious to see your top suppliers emissions?
Book a demo for a pilot project
Book a demo for a pilot project
Guardant Health, Inc., a leading precision oncology company, is headquartered in the United States, with significant operations across North America and Europe. Founded in 2012, the company has rapidly established itself in the biotechnology industry, focusing on non-invasive cancer detection and monitoring through advanced genomic testing.
Guardant Health is renowned for its flagship product, the Guardant360® test, which provides comprehensive genomic profiling of solid tumours using a simple blood draw. This innovative approach allows for personalised treatment strategies, setting the company apart in the competitive landscape of cancer diagnostics.
With a strong market position, Guardant Health has achieved notable milestones, including partnerships with major pharmaceutical companies and contributions to pivotal clinical trials. Its commitment to transforming cancer care through cutting-edge technology continues to drive its success in the oncology sector.
-4 vs industry average
Guardant Health’s score of 36 is higher than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
In 2023, Guardant Health, headquartered in the US, reported total emissions of approximately 4,222,000 kg CO2e, comprising 1,659,000 kg CO2e from Scope 1 and 2,563,000 kg CO2e from Scope 2 emissions. Notably, the company has not disclosed any Scope 3 emissions data.
Guardant Health has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 emissions to near zero by 2025. Additionally, the company has committed to a 42% reduction in absolute Scope 1 and Scope 2 greenhouse gas emissions by 2030, using 2023 as the base year. Furthermore, Guardant Health plans to reduce its Scope 3 emissions from various categories, including purchased goods and services, by 25% within the same timeframe.
These targets align with the Science Based Targets initiative (SBTi) and reflect Guardant Health's commitment to addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector.
Access structured emission data, company specific factors and auditable source documents
2030
42% reduction in Scope 2
Guardant Health, Inc. commits to reduce absolute scope 2 GHG emissions 42.0% by 2030 from a 2023 base year.
2030
42% reduction in Scope 1
Guardant Health, Inc. commits to reduce absolute scope 1 GHG emissions 42.0% by 2030 from a 2023 base year.
2030
25% reduction in scope 3 total
Guardant Health, Inc. also commits to reduce absolute scope 3 GHG emissions from purchased goods and services, fuel- and energy-related acti…
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


Common questions about Guardant Health’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more